

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

During the committee meeting, a clinical expert highlighted that tisotumab vedotin is given every 3 weeks, compared with weekly paclitaxel (given consecutively for 3 weeks followed by 1-week off). They added that weekly administration may be limiting for people with difficulty accessing transport. As most people in the target population currently receive weekly paclitaxel, the clinical expert highlighted that there may be benefits associated with the reduced administration frequency of tisotumab vedotin.

The committee acknowledged that access to tisotumab vedotin may have a greater impact on people who have difficulty accessing transport. It thought the reduced administration frequency could play a role in reducing health inequalities and took this into account when determining its preferred ICER threshold.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes- see final draft guidance sections 3.16 and 3.17

Approved by Principle Technical Adviser (name): Lizzie Walker

Date: 05.05.2026